Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans

F Lanzarotto, B Panarotto, R Sorbara, M Panteghini, F Pagani, S Sosta, A Lanzini

Abstract
Background—Stimulated bile acid synthesis preferentially utilises newly synthesised cholesterol, raising the possibility that combination of simvastatin (an inhibitor of cholesterol synthesis) with ursodeoxycholic acid (UDCA; a stimulator of bile acid synthesis) may result in reduced bile acid synthesis and greater enrichment of the pool with UDCA than that achieved with UDCA treatment alone.

Aims—To investigate the effect of simvastatin and UDCA given alone and in combination on serum and biliary lipid and biliary bile acid composition.

Methods—Eighteen patients with primary non-familial hypercholesterolaemia were studied during treatment with simvastatin 20 mg/day, UDCA 10 mg/kg/day, and a combination of the two drugs. Each regimen was given in random order for three months following a three month lead in period.

Results—Simvastatin significantly reduced serum low density lipoprotein (LDL) cholesterol but biliary cholesterol concentration remained unchanged. Combination of the two drugs had no synergistic effect on serum cholesterol concentration, but significantly increased the proportion of UDCA in the bile acid pool from 35% during UDCA to 48% during combination treatment (p<0.04).

Conclusions—Results showed that: (1) simvastatin reduces serum LDL cholesterol but has no effect on biliary cholesterol concentration, supporting the concept that newly synthesised cholesterol is not the preferential source for biliary cholesterol; and (2) combination of simvastatin with UDCA has the predicted effect of enhancing the proportion of UDCA in the pool. This effect may be of benefit in the treatment of cholestatic liver diseases.

Key words: simvastatin; HMG-CoA reductase inhibitors; ursodeoxycholic acid; bile; lipids; hypercholesterolaemia; simvastatin

It is well documented that administration of statins reduces serum low density lipoprotein (LDL) cholesterol by a mechanism involving inhibition of 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA reductase) activity, the rate limiting step in hepatic cholesterol synthesis.1 In addition to their effect on serum lipids, statins have also been reported to influence biliary lipid composition, but the evidence for this phenomenon is conflicting.2–13 Thus acute administration of simvastatin to cholecystectomised normalipaemic patients has been reported by Loria and colleagues14 to reduce hepatic bile acid secretion with no effect on cholesterol secretion. An opposite effect has been reported by Mazzella and colleagues15 during short term administration of simvastatin to hypercholesterolaemic patients. Furthermore, the cholesterol saturation index (SI) of gall bladder bile has been reported to be reduced by some16 but not all17 authors during short term administration of simvastatin, pravastatin, or lovastatin. Differences in patient selection, length of treatment,15 or pre-treatment cholesterol SI17 may explain these discrepancies, and the effect of statins on biliary lipids is still not certain.

In contrast to the statins, it is well documented that administration of ursodeoxycholic acid (UDCA) reduces biliary cholesterol secretion and cholesterol SI of gall bladder bile.16 UDCA is known to cause intestinal cholesterol malabsorption,15 16 and to stimulate bile acid synthesis from cholesterol as it also causes intestinal bile acid malabsorption.17 18 It has been suggested that these two effects may increase the hepatic need for cholesterol, thus stimulating the hepatic uptake of LDL,19 but reduced serum LDL cholesterol concentration has been an inconsistent finding during UDCA treatment.14 15 19

It is conceivable that when combinations of statins and UDCA are given, the combination of inhibition of cholesterol synthesis with increased bile acid synthesis from cholesterol may have a synergistic effect on both serum and biliary lipid composition; evidence for this latter effect has been reported.5 6 As bile acid synthesis preferentially utilises newly synthesised cholesterol under conditions of stimulated bile acid formation,6 20 we also reasoned that inhibition of hepatic cholesterol synthesis with simvastatin during stimulation of bile acid synthesis preferentially utilises newly synthesised cholesterol under conditions of stimulated bile acid formation,6 20 we also reasoned that inhibition of hepatic cholesterol synthesis with simvastatin during stimulation of bile acid synthesis...

Abbreviations used in this paper: HDL, high density lipoprotein; HMG-CoA reductase, 3-hydroxy-3-methylglutaryl CoA reductase; LDL, low density lipoprotein; SI, saturation index; UDCA, ursodeoxycholic acid; VLDL, very low density lipoprotein.
Simvastatin as an adjunct to ursodeoxycholic acid

Patients and methods

Patients
A total of 18 patients (11 men, seven women), aged 38–68 years (mean (SD) 54 (2) years), with a body mass index of 22–26 kg/m² (mean 23 (1) kg/m²) was studied. All patients were diagnosed as having primary non-familial hypercholesterolaemia without complications. All patients were gallstone-free as judged by abdominal ultrasonography. No patient was receiving drugs known to influence serum lipid concentrations for three months before entering the study. The study protocol was approved by the local ethics committee, and all patients were asked to sign an informed consent form before entering the study.

Experimental design and clinical procedure
Selected patients were followed up at monthly intervals for three months prior to randomisation (dietary lead in period) and during administration of simvastatin alone, UDCA alone, and their combination, given for three months each to patients with primary non-familial hypercholesterolaemia. A carefully monitored dietary lead in period of three months preceded randomisation to treatment to ensure steady state conditions prior to the start of the study.

Laboratory methods

Bile acid, cholesterol, and phospholipid concentrations in bile samples were measured enzymatically as previously described. Bilary bile acid composition was measured by HPLC as described by Ruben et al. Briefly, bile acids were extracted from whole bile samples using silica bonded cartridges (Bond-Elut) and eluted with pure methanol. Conjugated bile acids were analysed by isocratic high pressure liquid chromatography using a Waters LC Module 1 apparatus equipped with a Waters Bondpack C-18 10 µm column, and methanol:phosphate buffer (1:2) as mobile phase (pH 5.2, flow rate 1 ml/min, and detection at 200 nm).

Serum cholesterol and triglyceride concentrations were measured using an automated enzymatic technique (Boehringer Mannheim Test Combination Cholesterol and Tryglycerides, respectively). High density lipoprotein (HDL) cholesterol was measured in the supernatant following precipitation of LDL and very low density lipoprotein (VLDL) cholesterol. LDL cholesterol was calculated using the formula of Friedewald and Levy. Serum apolipoprotein A-I and B concentrations were measured by using the radial immunodiffusion technique.

Calculation and expression of results

Cholesterol SI of gall bladder bile was calculated using Carey’s critical tables assuming total lipid concentration at 10 g/dl. The Carey’s correction factor for percentage UDCA in bile was also applied. The hydrophobicity index of biliary bile acids was calculated as described by Heuman. The serum atherogenic index was calculated as LDL:HDL cholesterol ratio.

Results

All 18 patients admitted to the study completed the study period and regularly attended the clinic for blood sample collections. Three of the eight patients enrolled for the biliary lipid study missed one of the four scheduled bile collections (at baseline, during simvastatin, and during simvastatin + UDCA, in individual patients respectively) due to lack of compliance with repeated nasoduodenal intubations.

Effect on serum lipids and atherogenic index
Total serum cholesterol and triglyceride concentrations remained stable during the three months dietary lead in period (table 1). The
The mean value for the total serum cholesterol concentration decreased from 308 (12) mg/dl at enrolment to 237 (16) mg/dl at three months during simvastatin (p<0.0001), and remained unchanged at 297 (12) mg/dl (NS) during treatment with UDCA. The serum atherogenic index as expressed by the LDL:HDL ratio was reduced during simvastatin, but UDCA given alone or in combination had no effect (table 1 and fig 1).

The mean value for the serum triglyceride concentration decreased during simvastatin in comparison with the pretreatment value, but did not significantly change during UDCA given alone or in combination with simvastatin (table 1). The mean value for the apolipoprotein A-I concentration remained unchanged during each of the three regimens studied. The mean value for apolipoprotein B decreased significantly during simvastatin treatment in comparison with the pretreatment value (125 (16) versus 165 (15) mg/dl, respectively, p<0.002), but UDCA given alone or in combination had no effect (table 1).

### EFFECT ON BILIARY LIPID AND CHOLESTEROL SATURATION INDEX

Figure 2 shows values for the cholesterol SI of gall bladder bile in individual subjects. The mean value was 1.20 (0.10) before treatment and remained virtually unchanged at 1.08 (0.12) during simvastatin (NS). The cholesterol SI was significantly lower during UDCA than before treatment (0.83 (0.08) versus 1.20 (0.10), respectively, p<0.02), and was further decreased during combination treatment (0.54 (0.01); p<0.02 in comparison with pretreatment, and p<0.05 in comparison with UDCA alone).

### EFFECT ON BILIARY BILE ACID AND HYDROPHOBICITY INDEX

Biliary bile acid composition was not affected by simvastatin (table 2). In contrast, the percentage of UDCA in gall bladder bile significantly increased from a mean value of 2.5 (0.3)% pretreatment to 35.2 (5.3)% during UDCA (p<0.004). The enrichment of bile with UDCA further increased to 47.6 (4.9)% during combination treatment (p<0.002 in comparison with pretreatment), and this value was also significantly higher than that observed during UDCA alone (p<0.04). This effect of UDCA alone and in combination with simvastatin on the percentage of UDCA in bile was mirrored by a significant reduction in both cholic and chenodeoxycholic acid concentrations (table 2).

The mean value for the hydrophobicity index of biliary bile acids was 0.32 (0.02) before treatment; it was not affected by simvastatin (0.30 (0.01), NS) but it was significantly reduced during UDCA treatment (0.08 (0.04), p<0.002 in comparison with pretreatment). Combination of UDCA with simvastatin further reduced the hydrophobicity index (−0.01 (0.04)), but the difference with UDCA alone did not reach statistical significance.

The cholesterol SI of gall bladder bile was positively related to the hydrophobicity index of biliary bile acids ($y = 1.5229x + 0.6388; r=0.697, p<0.001$), but there was no relation between the latter and the atherogenic index.

### Discussion

Our study aimed primarily to check whether simvastatin and UDCA have a synergistic effect on serum and biliary lipid concentrations and on bile acid composition by comparing their effect when given in combination with

---

### Table 1  Effect of simvastin and UDCA on serum lipids and the atherogenic index

<table>
<thead>
<tr>
<th></th>
<th>Enrolment</th>
<th>Lead in 1 month</th>
<th>Lead in 2 months</th>
<th>Lead in 3 months</th>
<th>Simvastin</th>
<th>UDCA</th>
<th>Simvastin + UDCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholesterol (mg/dl)</td>
<td>303 (12)</td>
<td>303 (13)</td>
<td>310 (10)</td>
<td>308 (12)</td>
<td>237 (16)*</td>
<td>297 (12)</td>
<td>253 (14)*</td>
</tr>
<tr>
<td>LDL:HDL ratio</td>
<td>3.7 (0.3)</td>
<td>2.2 (0.3)‡</td>
<td>3.0 (0.3)</td>
<td>3.0 (0.3)</td>
<td>2.3 (0.3)‡</td>
<td>2.3 (0.3)‡</td>
<td>2.3 (0.3)‡</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>201 (28)</td>
<td>149 (30)‡</td>
<td>216 (35)</td>
<td>174 (24)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apolipoprotein A-I (mg/dl)</td>
<td>155 (7)</td>
<td>157 (10)</td>
<td>169 (7)</td>
<td>154 (11)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apolipoprotein B (mg/dl)</td>
<td>165 (15)</td>
<td>125 (16)†</td>
<td>151 (11)</td>
<td>126 (16)†</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results expressed as mean (SEM).

*p<0.0001, †p<0.002, ‡p<0.003, §p<0.03 compared with pretreatment.

---

**Figure 1** Effect of simvastatin and UDCA given alone or in combination on the atherogenic index (LDL:HDL cholesterol ratio) in individual patients.

**Figure 2** Effect of simvastatin and UDCA given alone or in combination on the cholesterol SI of gall bladder bile in individual patients.
that when given alone. The well known ability of simvastatin to reduce total serum cholesterol and apolipoprotein B concentration was confirmed in our study. This effect was mainly due to a reduction in serum LDL concentrations resulting in a reduced LDL: HDL cholesterol ratio (fig 1), a reduction that has been reported to be associated with an antiatheroma effect.1

In contrast with simvastatin, UDCA given alone had no effect on total serum cholesterol or on the LDL: HDL cholesterol ratio. This observation is similar to that obtained in studies involving long term UDCA treatment for gallstone dissolution using the conventional 10–12 mg/kg/day UDCA dose.14 In contrast with these observations, Eusufzai and colleagues15 have reported reduced LDL cholesterol in five healthy normolipaemic subjects treated with 30 mg/kg/day UDCA, and a similar trend for 15 mg/kg/day UDCA. Taken together these results raise the possibility of a dose response effect of UDCA on serum cholesterol, and suggest that very high dose UDCA may be necessary to stimulate bile acid synthesis under conditions of increased demand.

We also tested the effect of inhibiting HMG-CoA reductase with simvastatin on biliary cholesterol concentrations and found no effect (fig 2). This observation is in keeping with the concept that cholesterol for biliary secretion is derived mainly from a preformed pool of serum LDL rather than from de novo hepatic synthesis.12 Supporting evidence for this concept has been elegantly provided by recent work of Hillebrant and colleagues33 in a study involving measurement of biliary lipid secretion in cholecystectomised patients during removal of serum LDL by apheresis and preservation of HDL. In this study the acute reduction in serum LDL concentration was accompanied by decreased bile acid and phospholipid secretion, and by unchanged cholesterol secretion. Unchanged HDL cholesterol and decreased serum LDL concentrations have also been reported by Loria and colleagues,2 to be accompanied by unchanged cholesterol and decreased bile acid secretion in bile during acute simvastatin administration in cholecystectomised patients. Furthermore, increased biliary cholesterol secretion has been observed by Kozarski and colleagues36 using a murine model with an overexpressed HDL receptor enhancing hepatic uptake of this lipoprotein. These results are consistent with our finding that inhibition of hepatic cholesterol synthesis has little effect on biliary cholesterol secretion, and with the concept that unesterified cholesterol carried as HDL is the preferential source of biliary cholesterol.

The lack of effect of simvastatin in reducing biliary cholesterol SI observed in the present and in other studies is indirectly supported by the clinical observation that chronic administration of simvastatin has been reported by van Erpecum and colleagues3 to have no effect on dissolution of small radiolucent gallstones. The reason why other authors have reported an effect of simvastatin in reducing biliary cholesterol secretion or concentration34 is unclear. Differences in experimental conditions may help to explain these discrepancies. Thus, for example, the same group of investigators have reported decreased and unchanged biliary cholesterol secretion during simvastatin administration in hypercholesterolaemic patients3 and in obese subjects during weight reduction16 respectively.

Combination of simvastatin significantly increased the proportion of UDCA in the pool in comparison with UDCA alone (table 2). Although these results are based on bile analysis in only six patients, the evidence for a synergistic effect of simvastatin and UDCA on the proportion of UDCA in the pool is strengthened by the observation that this effect was present in each patient. The size of this synergistic effect was not very large, but it was large enough to influence the cholesterol SI of gall bladder bile, which was lower during combination therapy than during UDCA alone. This finding of an increased proportion of UDCA in the pool during combination therapy is novel and the mechanism involved is unknown. A possible interpretation is based on the observations that, as mentioned above, chronic UDCA administration is known to stimulate bile acid synthesis preferentially utilises newly synthesised cholesterol.20 Results consistent with this concept have been reported by Hillebrandt and colleagues37 in cholecystectomised patients with biliary diversion studied before and after inhibition of cholesterol synthesis by pravastatin. These authors reported increased secretion of bile acids and phospholipolipid but no change in cholesterol secretion during increased cholesterol synthesis at cessation of pravastatin, a finding consistent with a high dependency of bile acid synthesis on de novo cholesterol synthesis under conditions of increased demand for bile acids.

In conclusion, our study indicates that a standard UDCA dose of 10 mg/kg/day has no synergistic effect with simvastatin in reducing serum LDL concentration. Simvastatin has no effect on biliary lipid composition when given alone, but combination with UDCA results in greater enrichment of the bile acid pool with this bile acid in comparison with UDCA given alone. This latter effect may be important in clinical practice for treatment of cholestatic
liver diseases, and needs to be confirmed in an adequate number of patients with conditions such as primary biliary cirrhosis where the benefit of UDCA is likely to depend on the extent of enrichment of the pool with UDCA. 


2 Lanzarotto, Panarotto, Sorbara, et al


10 Lanzarotto, Panarotto, Sorbara, et al

11 Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the extent of enrichment of the pool with UDCA.37

12 Hoogerbrugge-vd Linden N, de Rooy FWM, Jansen H, et al


Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans

F Lanzarotto, B Panarotto, R Sorbara, M Panteghini, F Pagani, S Sosta and A Lanzini

Gut 1999 44: 552-556
doi: 10.1136/gut.44.4.552

Updated information and services can be found at:
http://gut.bmj.com/content/44/4/552

These include:

References
This article cites 34 articles, 11 of which you can access for free at:
http://gut.bmj.com/content/44/4/552#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/